AbbVie posts strong earnings beat on immunology portfolio

10 articles · Updated · The Wall Street Journal · May 1

The latest report says the drugmaker's immunology medicines drove results, while Wall Street remained jittery despite the earnings outperformance.
The report highlights a disconnect between strong quarterly execution and investor caution over the company's broader outlook.
AbbVie's performance suggests core products are still supporting growth, but market concerns continue to temper enthusiasm around the shares.

With Humira revenues plummeting and IRA price cuts looming, can AbbVie's innovation pipeline truly secure its future growth and investor confidence?

How might accelerating AI adoption and mounting cybersecurity threats reshape the balance between risk and reward for healthcare giants like AbbVie?

Will Medicare drug price negotiations ultimately help patients, or will they backfire by restricting access to innovative treatments?